Capricor Therapeutics (CAPR) AI Stock Analysis

• Market Cap: $468.51M
• Dividend Yield: N/A
• Average Volume (3M): 2.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.34
• Revenue Growth: -35.92%
• EPS Growth: -62.11%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 45,707,820
• 10 Day Avg. Volume: 4,182,128
• 30 Day Avg. Volume: 2,642,914
• PEG Ratio: -0.08
• Price to Book (P/B): 8.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 60.87
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: 0.05
• Enterprise Value/Gross Profit: 0.26
• Enterprise Value/Ebitda: -0.03
• 1Y Price Target: $33.11
• Price Target Upside: 223.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 52 Neutral
• Price Target: $10.00 ▼(-2.44%Downside)

Capricor Therapeutics faces financial challenges despite strategic advancements. While the company has strong potential with deramiocel approvals, negative profitability and cash flow issues pose significant risks. The positive sentiment from corporate events and strategic partnerships provide some support, but financial performance remains a primary concern.

Positive Factors

Financial Stability

Capricor has $145M in cash, providing runway into 2027.

Regulatory Progress

The manufacturing site inspection is on track and should be complete in the coming weeks, indicating readiness for the commercial launch.

Therapeutic Efficacy

Positive 4-year OLE data was presented at the Parent Project Muscular Dystrophy conference, showing that Deramiocel continues to preserve cardiac function and maintain a favorable long-term safety profile.

Negative Factors

Approval Probability

The probability of approval for deramiocel has been reduced to 45% from 65%.

Regulatory Challenges

The decision to submit the BLA without Phase 3 data happened under the prior FDA regime, and several top-ranking officials were recently dismissed.

Regulatory Risk

The FDA will not hold an Adcom meeting for deramiocel in Duchenne Muscular Dystrophy, increasing regulatory risk.

Capricor Therapeutics Business Overview & Revenue Model

Company Description

Capricor Therapeutics, Inc. (CAPR) is a biotechnology company focused on the development and commercialization of transformative cell and exosome-based therapeutics for the treatment of a variety of diseases. The company's core product candidates include CAP-1002, an allogeneic cardiac-derived cell therapy aimed at treating Duchenne muscular dystrophy (DMD) and other cardiac and inflammatory conditions. Capricor operates within the biopharmaceutical sector, leveraging its proprietary technologies to address unmet medical needs.

How the Company Makes Money

Capricor Therapeutics makes money primarily through the development and commercialization of its therapeutic candidates. The company's revenue model is centered around securing funding through collaborations, grants, and potential licensing agreements. Key revenue streams include partnerships with larger pharmaceutical companies, government grants, and research collaborations that provide financial support for its research and development activities. Additionally, Capricor aims to generate revenue through the eventual commercialization of its therapies, either independently or through strategic partnerships, once they receive regulatory approval. The company's progress in clinical trials and the successful development of its product pipeline are significant factors contributing to its earnings potential.

Capricor Therapeutics Financial Statement Overview

Summary

Capricor Therapeutics shows revenue growth but struggles with profitability and cash flow, typical challenges in biotechnology due to high R&D costs. The strong equity position mitigates some risk, but persistent losses are a concern.

Income Statement

Capricor Therapeutics has shown significant revenue volatility over the years, with a notable increase in revenue in 2023 compared to previous years, but still operates at a net loss. The gross profit margin is consistently negative, and the EBIT and EBITDA margins are also negative, indicating the company is struggling with profitability. Revenue growth is present but overshadowed by operational inefficiencies and high expenses.

Balance Sheet

The company has a strong equity position with a positive stockholders' equity, and the absence of total debt in the latest year indicates reduced leverage risk. However, the negative total liabilities figure in 2024 raises concerns about data accuracy or financial reporting issues. The equity ratio is favorable given the high equity levels in relation to assets.

Cash Flow

Capricor Therapeutics has experienced fluctuating cash flow from operations, with periods of negative free cash flow, indicating challenges in generating sustainable cash from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is not calculable, highlighting ongoing cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.36M	22.27M	25.18M	2.55M	244.90K	310.25K
Gross Profit	16.27M	20.84M	24.11M	1.86M	-798.00	310.25K
EBITDA	-55.78M	-41.14M	-23.01M	-29.16M	-20.69M	-13.55M
Net Income	-55.07M	-40.47M	-22.29M	-29.02M	-20.02M	-13.66M
Balance Sheet
Total Assets	153.77M	170.48M	58.73M	50.09M	41.33M	34.62M
Cash, Cash Equivalents and Short-Term Investments	144.78M	151.52M	39.49M	41.42M	34.89M	32.67M
Total Debt	1.25M	1.45M	2.24M	2.56M	2.87M	318.16K
Total Liabilities	26.12M	25.02M	36.13M	38.31M	9.96M	6.42M
Stockholders Equity	127.65M	145.46M	22.60M	11.79M	31.37M	28.20M
Cash Flow
Free Cash Flow	-47.18M	-41.53M	-27.64M	1.56M	-18.01M	-10.60M
Operating Cash Flow	-45.16M	-40.00M	-25.60M	4.92M	-16.81M	-10.05M
Investing Cash Flow	7.11B	-116.18M	5.11M	-35.07M	-1.20M	5.44M
Financing Cash Flow	150.53M	152.77M	25.58M	4.87M	20.23M	33.38M

Capricor Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPR, the sentiment is Negative. The current price of 10.25 is below the 20-day moving average (MA) of 11.33, below the 50-day MA of 10.72, and below the 200-day MA of 13.62, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 47.85 is Neutral, neither overbought nor oversold. The STOCH value of 66.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPR.

Capricor Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TBPH	57 Neutral	$557.51M	―	-31.46%	―	6.11%	-37.79%
CAPR	52 Neutral	$468.51M	―	-75.39%	―	-35.92%	-62.11%
AKBA	49 Neutral	$950.74M	―	91.25%	―	-17.75%	-19.17%
Sector *	49 Neutral	AU$2.50B	4.42	-64.25%	2.77%	36.51%	13.14%
KROS	46 Neutral	$546.28M	―	0.71%	―	91657.69%	97.21%
TYRA	41 Neutral	$531.78M	―	-27.04%	―	―	6.72%
MNMD	40 Neutral	$541.72M	―	-37.07%	―	―	26.24%

Capricor Therapeutics Corporate Events

Capricor Therapeutics Approves 2025 Equity Incentive Plan

Capricor Therapeutics, Inc. announced that its stockholders approved the 2025 Equity Incentive Plan during the 2025 Annual Meeting of Stockholders. This plan, previously approved by the Board of Directors, reserves 3,500,000 shares of common stock for equity-based awards to employees, non-employee directors, and consultants, with an automatic annual increase in shares authorized for issuance starting January 1, 2026, through January 1, 2035. This development is expected to enhance the company’s ability to attract and retain talent, thereby potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (CAPR) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Capricor Therapeutics stock, see the CAPR Stock Forecast page.